Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416

NCT00680485 | Terminated Phase 1

• 1 other identifier: OPS108221
• Study Type: interventional
• Target: 96
• Locations: 1 country
• Sites: 1

Brief Summary

This study will evaluate the safety, tolerability and exposure of repeat escalating oral doses, a loading dose/maintenance dose regimen of GSK580416 and when co administered with ketoconazole, a PGP/CYP3A4 inhibitor.

Conditions

Bacterial Infection; Infections, Bacterial

Keywords

GSK580416; ketoconazole interaction; pleuromutilin; oral dose

Outcome Measures

Primary Outcomes (1)

• Safety and tolerability of GSK580416 doses determined from clinical safety and tolerability data from all adverse event reporting, 12-lead ECGs, vital signs, nursing/physician observation, and safety laboratory tests

Secondary Outcomes (1)

• Pharmacokinetics of GSK580416 as determined by AUC, Cmax, tmax, half-life, and Ct.

Interventions

GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg) DRUG

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adults (as determined by medical evaluation including history, physical exam, vital signs, laboratory tests, and cardiac monitoring)
• Aged 18-60yrs, with BMI of 19-31kg/m2.
• Females must be of non-childbearing potential.
• QTc \< 450 msec at screening.
• Subjects must be able to give consent and comply with restrictions of study.

You may not qualify if:

• Clinically significant CNS, cardiac, pulmonary, metabolic, renal, hepatic or GI condition or history that may place the subject at an unacceptable risk or may interfere with absorption, distribution, metabolism, or excretion of drug.
• Positive urine drug screen.
• Positive urine test for alcohol.
• Positive HIV or Hep B and/or C assay.
• History of regular tobacco use within 3 monts prior to screening or cotinine levels indicative of smoking at screening.
• History of regular alcohol consumption (14 units/week for women and 21 units/week for men).
• History of drug abuse or dependence within 12 months of study.
• Participation in another drug trial within 30 days of first dose.
• Exposure to more than 4 new chemical entities within 12 months of first dose.
• Use of prescription and non-prescription drugs including vitamins, dietary supplements, herbals within 7 days of first dose or St. John's Wort within 28 days of the first dose.
• Consumption of red wine, Seville oranges, grapefruit, or grapefruit juices within 14 days of first dose.
• Donation of blood in excess of 500 mL within 56 days of dosing. No blood donation is allowed 30 days prior to study participation.
• A positive immunochemical fecal occult blood test at screening.
• History of sensitivity to any of the study medications.
• History of sensitivity to heparin or heparin-induced thrombocytopenia.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Adelaide, South Australia, 5000, Australia

Location

MeSH Terms

Conditions

Bacterial Infections

Interventions

Ketoconazole

Condition Hierarchy (Ancestors)

Bacterial Infections and Mycoses; Infections

Intervention Hierarchy (Ancestors)

Piperazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 14, 2008
• First Posted: May 20, 2008
• Study Start: June 1, 2007
• Primary Completion: October 1, 2007
• Study Completion: October 1, 2007
• Last Updated: January 20, 2017

Record last verified: 2017-01

Locations

AU (1)